Mathematics specialist by training, Clémentine BODY began her career in Leem, the French association of pharmaceutical companies in France. In that role, she was directly involved in negotiations with French Authorities on Social security Financing Laws and medicine’s price agreement. In 2017, she joined Merck company (known as MSD outside USA) as Pricing and reimbursement specialist for Keytruda, an anti-PD1 monoclonal antibody indicated in different type of cancers. In 2018, she joined Biogen where she leaded the market access for Spinraza in France, the 1st drug indicated in spinal muscular atrophy (SMA), a rare genetic neuromuscular disease. In 2022, she was appointed Market Access Director for France, Belgium, Netherlands and Luxembourg of Stemline, a spin-off of the Italian company Menarini. In that role, she leaded market access of three oncology drugs for these four countries. In 2023, she joined the Health Innovation Agency, as Transversal Projects and International Director. The Health innovation Agency was created in 2022, with the aim to foster and coordinate the inter-ministerial works on innovation in health.